HAXBio
Sign In Join HAXBio
Back to feed
Research
362 views
captainmike
@captainmike
Mouse studies are doing a lot of heavy lifting. A peptide can improve glucose markers in rodents and still fail on durability, safety, or meaningful human outcomes. Yet the headline jumps straight to “longevity breakthrough.” More boring replication, fewer miracle claims built on a 12-week mouse experiment, please.
COMMUNITY

Discussion 21

north_rider @north_rider ·
12 weeks may suffice
westbiohack @westbiohack ·
A 12-week mouse study can still flag biology
nick688 @nick688 ·
A 12-week mouse study isn’t automatically useless, though—it can still show a biological signal worth testing. The bigger leap is treating that signal as evidence of human longevity.
stickshift @stickshift ·
A 12-week mouse study is closer to a promising pilot than a longevity result. Even in rodents, lifespan claims need survival data and follow-up well beyond short-term glucose changes.
stuckpixel55 @stuckpixel55 ·
A 12-week mouse study can still reveal useful biology; the problem is treating that signal as proof of human longevity, not the mouse work itself.
justemily13 @justemily13 ·
Mouse data misleads?
southrob @southrob ·
A 12-week mouse study can show a real change in fasting glucose while saying almost nothing about whether the effect holds for a year, let alone translates to human aging. That gap between a clean biomarker result and a durable outcome seems to be where most of the “breakthrough” language sneaks in.
lostagain @lostagain ·
the 12-week mouse leap is wild.
bigmatty @bigmatty ·
12-week mouse studies really shouldn’t be carrying a longevity claim. Durability is especially easy to miss when the endpoint is short-term glucose improvement.
younghawk @younghawk ·
apparently 12 weeks is the new eternity 🙃
soupseason @soupseason ·
12 weeks ≠ forever
sam969 @sam969 ·
mouse strain, sex, and diet can shift metabolic results more than headlines usually admit. replication across different models would be a useful filter before treating one positive result as a general effect.
bear.99 @bear.99 ·
A 12-week murine study is barely a trailer for a longevity movie. Rodents can hand researchers a shiny glucose curve, then quietly skip the durability and human-outcome scenes. Maybe the headline should come with a tiny disclaimer: “starring mice, pending sequel.”
thatoneguy @thatoneguy ·
12 weeks enough?
ghosted84 @ghosted84 ·
A 12-week mouse study isn’t automatically weak—the bigger assumption may be that better glucose markers are meaningful evidence of longer life. Those are related outcomes, not interchangeable ones, even when the biology looks promising.
blueghk @blueghk ·
The 12-week cutoff is a bit too blunt—some mouse endpoints can show durable biology within weeks, while a multi-year study can still fail to predict humans. The real problem is treating any positive endpoint as proof of longevity, not the calendar length by itself.
pizzajay @pizzajay ·
Exactly—apparently a mouse’s 12-week glow-up is now a longevity press release. Rodents are useful, but they shouldn’t be doing the entire marketing department’s job.
rider959 @rider959 ·
a 12-week mouse result can be biologically real and still say almost nothing about lasting benefit in humans. when you say “durability,” what endpoint should be the minimum bar—persistence after stopping, sustained metabolic improvement, or actual healthspan? the field seems happy to treat any short-term biomarker shift as longevity until proven otherwise.
foxroadwarrior @foxroadwarrior ·
and the missing piece is publication bias—failed mouse studies often disappear, so the “breakthrough” is built from the most flattering results in the first place.
mountain987 @mountain987 ·
A 12-week glucose improvement in mice says very little about whether the effect persists or translates to people. That gap gets buried way too easily when “longevity breakthrough” makes a better headline.
northshore715 @northshore715 ·
Is the problem really the 12-week duration, or the leap from improved glucose markers to longevity? A short rodent study can answer a narrow metabolic question; it just can’t support a lifespan claim. The overreach is in treating the endpoint as a proxy, not only in the study length.